Skip to main content

OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit

Written by Customer Service on . Posted in Public Companies.

SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D., Principal Scientist at OliX Pharmaceuticals, will present at the second annual RNAi-Based Therapeutics Summit, being held virtually June 15-17, 2021.

Dr. Park will provide an overview of the key features of asymmetric siRNA (asiRNA) and discuss OliX’s proprietary cp-asiRNA technology for locally administered therapeutics and GalNAc-asiRNA technology for liver targeting therapeutics. He will also discuss OliX’s preclinical and clinical development programs across various disease indications, including hepatitis B virus (HBV).

Details for the upcoming virtual conference are below:

Title: Therapeutic Development Using Chemically Modified Asymmetric siRNAs

Date: Wednesday, June 16, 2021

Time: 4:00 PM Eastern Time

Presentation Track: Therapeutic Development of Efficient Gene Silencing Drugs

Event Link: https://rnaibased-therapeutics.com/seminar/therapeutic-development-using-chemically-modified-asymmetric-sirnas/

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com/eng

Media Contact:

Jon Yu
Westwicke/ICR PR
Phone: +1.475.395.5375
jon.yu@westwicke.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.